Press Release FeedGet the RSS feed
Menu

Business Wire

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Business Wire

  • The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2

  • The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7

  • This approval underscores Galderma's continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide

ZUG, Switzerland, October 23, 2026--Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company's Injectable Aesthetics portfolio in China – one of the world's largest and fastest-growing aesthetics markets.8,9 This approval follows successful authorizations and launches of Relfydess in more than 35 markets worldwide.

Relfydess is the first and only ready-to-use liquid neuromodulator developed with PEARL Technology, designed to deliver a highly active, innovative, complex-free molecule that addresses the real needs of patients and healthcare professionals.1,2,4,5 It is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.1,10

At a time when patients and healthcare professionals are increasingly seeking high-performance neuromodulators that rapidly deliver long-lasting, natural-looking outcomes, Relfydess' introduction to China will help to meet the increasing needs of this large and diverse market by providing an innovative new treatment option.11 Insights from a Galderma survey on anti-wrinkle treatments indicate that the market is set to expand further, with 97% of surveyed patients in China indicating they plan to maintain or increase their use in the future.11 Additionally, the survey found that 88% of Chinese patients ranked natural-looking results as one of their top three treatment benefits, and 86% ranked long lasting results up to six months in their top three.11

"Relfydess represents a breakthrough in neuromodulation, the first in decades. As a clinician, I have seen patients increasingly seek treatments that fit seamlessly into their lifestyles, delivering both rapid onset and long-lasting results. With its ready-to-use liquid formulation requiring no reconstitution, Relfydess also offers a new level of convenience and innovation. I am delighted to bring this treatment to aesthetic patients in China and help usher in a new era in neuromodulation."

PROF. WU YAN

CHIEF PHYSICIAN OF DERMATOLOGY DEPARTMENT

PEKING UNIVERSITY FIRST HOSPITAL, CHINA

  1. Issue of EquityLONDON, October 23, 2026--This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory informati
  2. Marketing & advertisingGumGum81.5% of U.S. Marketers Surveyed Say Mindset Advertising Can Outperform Identity-Based TargetingGumGum Report Finds Marketers Back Mindset Advertising But Struggle to Activate It SANTA MONICA, Calif., October 23, 2026--GumGum , the Mindset Company™ transforming advertising, today announced the release of The Marketers' Take On Mindset: 2026 Global Report, revealing that marketers increasingly se
  3. EnergyEnergy Impact PartnersEnergy Impact Partners Deepens Partnership with Singapore Economic Development Board to Advance Energy Innovation & DecarbonisationEIP and the Singapore Economic Development Board (EDB) expand their collaboration to connect EIP's global network with Singapore's energy transition and decarbonisation ecosystem Partnership supports Singapore's Decarbonisation Grand Challenge by creating pathways for promising companies to develop and scale from Singapor
  4. EnergyEverGen Infrastructure Corp.EverGen Infrastructure Announces Record RNG Production for Q3 2026VANCOUVER, British Columbia, October 23, 2026--EverGen Infrastructure Corp. ("EverGen" or the "Company") (TSXV: EVGN) (OTCQB: EVGIF) is pleased to announce production results for the quarter ending September 30, 2026. Quarterly RNG Production Update The Company delivered its highest quarterly Renewable
  5. InsuranceAM Best to Present and Participate at 2026 Shanghai International Reinsurance ConferenceHONG KONG, October 23, 2026--Members of AM Best's analytic team will deliver outlook presentations on China's non-life insurance segment and the global and Asian reinsurance markets at the 2026 Shanghai International Reinsurance Conference, which will take place 27-30 October 2026 in Shanghai, China. O
  6. FinanceZai Lab LimitedZai Lab Announces $250 Million Private PlacementSHANGHAI & CAMBRIDGE, Mass., October 23, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares ("ADSs"), each representing ten ordina